Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease

NeuroMolecular Medicine

Volumn 16, Issue 1, 2014, Pages 25-37

  Rué, Laura ^a,b,c   Alcalá Vida, Rafael ^a,b,c   López Soop, Graciela ^a,b,c   Creus Muncunill, Jordi ^a,b,c   Alberch, Jordi ^a,b,c   Pérez Navarro, Esther ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cell death; Huntingtin; Lamin B; PKC dominant negative

Indexed keywords

ANIMALS; APOPTOSIS; CELL NUCLEUS; CEREBRAL CORTEX; CORPUS STRIATUM; CYTOPLASM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; LAMIN TYPE B; MALE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN KINASE C BETA; PROTEIN KINASE C-ALPHA; PROTEIN KINASE C-DELTA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PUTAMEN; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; UBIQUITINATION;

EID: 84894248353     PISSN: 15351084     EISSN: 15591174     Source Type: Journal    
DOI: 10.1007/s12017-013-8248-8     Document Type: Article

References (68)

1. Alkon, D. L., Sun, M. K., & Nelson, T. J. (2007). PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease. Trends in Pharmacological Sciences, 28(2), 51-60.
2. Anantharam, V., Kitazawa, M., Wagner, J., Kaul, S., & Kanthasamy, A. G. (2002). Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. Journal of Neuroscience, 22(5), 1738-1751.
3. Anglada-Huguet, M., Giralt, A., Perez-Navarro, E., Alberch, J., & Xifro, X. (2012). Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease. Journal of Neurochemistry, 121(4), 639-648.
4. Battaini, F., & Pascale, A. (2005). Protein kinase C signal transduction regulation in physiological and pathological aging. Annals of the New York Academy of Sciences, 1057, 177-192.
5. Brodie, C., & Blumberg, P. M. (2003). Regulation of cell apoptosis by protein kinase c delta. Apoptosis, 8(1), 19-27.
6. Brognard, J., & Newton, A. C. (2008). Phlipping the switch on Akt and protein kinase C signaling. Trends in Endocrinology and Metabolism, 19(6), 223-230.
7. Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., Martin-Ibanez, R., Munoz, M. T., et al. (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. Journal of Neuroscience, 24(35), 7727-7739.
8. Costa, V., Giacomello, M., Hudec, R., Lopreiato, R., Ermak, G., Lim, D., et al. (2010). Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Molecular Medicine, 2(12), 490-503.
9. Crook, Z. R., & Housman, D. (2011). Huntington's disease: can mice lead the way to treatment? Neuron, 69(3), 423-435.
10. Cross, T., Griffiths, G., Deacon, E., Sallis, R., Gough, M., Watters, D., et al. (2000). PKC-delta is an apoptotic lamin kinase. Oncogene, 19(19), 2331-2337.
11. Dragatsis, I., Goldowitz, D., Del, M. N., Deng, Y. P., Meade, C. A., Liu, L., et al. (2009). CAG repeat lengths > or = 335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse. Neurobiology of Disease, 33(3), 315-330.
12. Eitel, K., Staiger, H., Rieger, J., Mischak, H., Brandhorst, H., Brendel, M. D., et al. (2003). Protein kinase C delta activation and translocation to the nucleus are required for fatty acid-induced apoptosis of insulin-secreting cells. Diabetes, 52(4), 991-997.
13. Enokido, Y., Tamura, T., Ito, H., Arumughan, A., Komuro, A., Shiwaku, H., et al. (2010). Mutant huntingtin impairs Ku70-mediated DNA repair. Journal of Cell Biology, 189(3), 425-443.
14. Fujii, T., Garcia-Bermejo, M. L., Bernabo, J. L., Caamano, J., Ohba, M., Kuroki, T., et al. (2000). Involvement of protein kinase C delta (PKCdelta) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCdelta. Journal of Biological Chemistry, 275(11), 7574-7582.
15. Gao, T., Brognard, J., & Newton, A. C. (2008). The phosphatase PHLPP controls the cellular levels of protein kinase C. Journal of Biological Chemistry, 283(10), 6300-6311.
16. Garcia-Martinez, J. M., Perez-Navarro, E., Xifro, X., Canals, J. M., Diaz-Hernandez, M., Trioulier, Y., et al. (2007). BH3-only proteins bid and bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease. Journal of Neuroscience Research, 85(12), 2756-2769.
17. Gines, S., Ivanova, E., Seong, I. S., Saura, C. A., & MacDonald, M. E. (2003). Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. Journal of Biological Chemistry, 278(50), 50514-50522.
18. Giralt, A., Saavedra, A., Carreton, O., Xifro, X., Alberch, J., & Perez-Navarro, E. (2011). Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Human Molecular Genetics, 20(21), 4232-4247.
19. Griner, E. M., & Kazanietz, M. G. (2007). Protein kinase C and other diacylglycerol effectors in cancer. Nature Reviews Cancer, 7(4), 281-294.
20. Harris, A. S., Denovan-Wright, E. M., Hamilton, L. C., & Robertson, H. A. (2001). Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice. Journal of Psychiatry and Neurosciences, 26(2), 117-122.
21. Hashimoto, T., Kitamura, N., Saito, N., Komure, O., Nishino, N., & Tanaka, C. (1992). The loss of beta II-protein kinase C in the striatum from patients with Huntington's disease. Brain Research, 585(1-2), 303-306.
22. Hongpaisan, J., & Alkon, D. L. (2007). A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proceedings of the National Academy of Sciences USA, 104(49), 19571-19576.
23. Hu, Y., Liu, Z., Yang, S. J., & Ye, K. (2007). Acinus-provoked protein kinase C delta isoform activation is essential for apoptotic chromatin condensation. Cell Death and Differentiation, 14(12), 2035-2046.
24. Humphries, M. J., Limesand, K. H., Schneider, J. C., Nakayama, K. I., Anderson, S. M., & Reyland, M. E. (2006). Suppression of apoptosis in the protein kinase Cdelta null mouse in vivo. Journal of Biological Chemistry, 281(14), 9728-9737.
25. Kaasinen, S. K., Goldsteins, G., Alhonen, L., Janne, J., & Koistinaho, J. (2002). Induction and activation of protein kinase C delta in hippocampus and cortex after kainic acid treatment. Experimental Neurology, 176(1), 203-212.
26. Klauck, T. M., Faux, M. C., Labudda, K., Langeberg, L. K., Jaken, S., & Scott, J. D. (1996). Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science, 271(5255), 1589-1592.
27. Koponen, S., Goldsteins, G., Keinanen, R., & Koistinaho, J. (2000). Induction of protein kinase Cdelta subspecies in neurons and microglia after transient global brain ischemia. Journal of Cerebral Blood Flow and Metabolism, 20(1), 93-102.
28. Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., & Foster, D. A. (1998). Activation of protein kinase C triggers its ubiquitination and degradation. Molecular and Cellular Biology, 18(2), 839-845.
29. Maher, P. (2001). How protein kinase C activation protects nerve cells from oxidative stress-induced cell death. Journal of Neuroscience, 21(9), 2929-2938.
30. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., et al. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87(3), 493-506.
31. Mann, D. M., Oliver, R., & Snowden, J. S. (1993). The topographic distribution of brain atrophy in Huntington's disease and progressive supranuclear palsy. Acta Neuropathologica, 85(5), 553-559.
32. Martin, J. B., & Gusella, J. F. (1986). Huntington's disease. Pathogenesis and management. New England Journal of Medicine, 315(20), 1267-1276.
33. Mochel, F., Durant, B., Meng, X., O'Callaghan, J., Yu, H., Brouillet, E., et al. (2012). Early alterations of brain cellular energy homeostasis in Huntington disease models. Journal of Biological Chemistry, 287(2), 1361-1370.
34. Mollersen, L., Rowe, A. D., Larsen, E., Rognes, T., & Klungland, A. (2010). Continuous and periodic expansion of CAG repeats in Huntington's disease R6/1 mice. PLoS Genetics, 6(12), e1001242.
35. Morton, A. J., Glynn, D., Leavens, W., Zheng, Z., Faull, R. L., Skepper, J. N., et al. (2009). Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiology of Disease, 33(3), 331-341.
36. Nelson, T. J., Sun, M. K., Hongpaisan, J., & Alkon, D. L. (2008). Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. European Journal of Pharmacology, 585(1), 76-87.
37. Ortega, Z., Diaz-Hernandez, M., Maynard, C. J., Hernandez, F., Dantuma, N. P., & Lucas, J. J. (2010). Acute polyglutamine expression in inducible mouse model unravels ubiquitin/proteasome system impairment and permanent recovery attributable to aggregate formation. Journal of Neuroscience, 30(10), 3675-3688.
38. Pineda, J. R., Pardo, R., Zala, D., Yu, H., Humbert, S., & Saudou, F. (2009). Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Molecular Brain, 2, 33.
39. Qi, X., Disatnik, M. H., Shen, N., Sobel, R. A., & Mochly-Rosen, D. (2011). Aberrant mitochondrial fission in neurons induced by protein kinase C{delta} under oxidative stress conditions in vivo. Molecular Biology of the Cell, 22(2), 256-265.
40. Rangone, H., Poizat, G., Troncoso, J., Ross, C. A., MacDonald, M. E., Saudou, F., et al. (2004). The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. European Journal of Neuroscience, 19(2), 273-279.
41. Ribeiro, F. M., Paquet, M., Ferreira, L. T., Cregan, T., Swan, P., Cregan, S. P., et al. (2010). Metabotropic glutamate receptor-mediated cell signaling pathways are altered in a mouse model of Huntington's disease. Journal of Neuroscience, 30(1), 316-324.
42. Ron, D., & Mochly-Rosen, D. (1994). Agonists and antagonists of protein kinase C function, derived from its binding proteins. Journal of Biological Chemistry, 269(34), 21395-21398.
43. Rosas, H. D., Koroshetz, W. J., Chen, Y. I., Skeuse, C., Vangel, M., Cudkowicz, M. E., et al. (2003). Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology, 60(10), 1615-1620.
44. Rybin, V. O., Guo, J., Gertsberg, Z., Elouardighi, H., & Steinberg, S. F. (2007). Protein kinase Cepsilon (PKCepsilon) and Src control PKCdelta activation loop phosphorylation in cardiomyocytes. Journal of Biological Chemistry, 282(32), 23631-23638.
45. Saavedra, A., Alberch, J., & Perez-Navarro, E. (2012). Don't take away my P: Phosphatases as therapeutic targets in Huntington's disease. In N. E. Tunali, (Ed.), Huntington's disease - Core concepts and current advances. Rijeka, Croatia: Intech.
46. Saavedra, A., Garcia-Martinez, J. M., Xifro, X., Giralt, A., Torres-Peraza, J. F., Canals, J. M., et al. (2010). PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3 K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death and Differentiation, 17(2), 324-335.
47. Saavedra, A., Giralt, A., Rue, L., Xifro, X., Xu, J., Ortega, Z., et al. (2011). Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity. Journal of Neuroscience, 31(22), 8150-8162.
48. Shin, E. J., Duong, C. X., Nguyen, T. X., Bing, G., Bach, J. H., Park, D. H., et al. (2011). PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment. Neurochemistry International, 59(1), 39-50.
49. Smith, R., Brundin, P., & Li, J. Y. (2005). Synaptic dysfunction in Huntington's disease: a new perspective. Cellular and Molecular Life Sciences, 62(17), 1901-1912.
50. Soh, J. W., & Weinstein, I. B. (2003). Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. Journal of Biological Chemistry, 278(36), 34709-34716.
51. Srivastava, J., Procyk, K. J., Iturrioz, X., & Parker, P. J. (2002). Phosphorylation is required for PMA- and cell-cycle-induced degradation of protein kinase Cdelta. Biochemical Journal, 368(Pt 1), 349-355.
52. Tanaka, C., Nishino, N., Hashimoto, T., Kitamura, N., Yoshihara, C., & Saito, N. (1993). Second messenger systems in brains of patients with Parkinson's or Huntington's disease. Advances in Neurology, 60, 175-180.
53. Tanaka, C., & Nishizuka, Y. (1994). The protein kinase C family for neuronal signaling. Annual Review of Neuroscience, 17, 551-567.
54. The Huntington's Disease Collaborative Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72(6), 971-983.
55. Van Der Hoeven, P. C., Van Der Wal, J. C., Ruurs, P., & Van Blitterswijk, W. J. (2000). Protein kinase C activation by acidic proteins including 14-3-3. Biochemical Journal, 347(Pt 3), 781-785.
56. Villalba, M. (1998). A possible role for PKC delta in cerebellar granule cells apoptosis. NeuroReport, 9(10), 2381-2385.
57. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., & Richardson, E. P, Jr. (1985). Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology, 44(6), 559-577.
58. Wahlin, T. B., & Byrne, G. J. (2012). Cognition in Huntington's disease. In N. E. Tunali (Ed.), Huntington's disease - Core concepts and current advances. Rijeka, Croatia: Intech.
59. Weeber, E. J., Atkins, C. M., Selcher, J. C., Varga, A. W., Mirnikjoo, B., Paylor, R., et al. (2000). A role for the beta isoform of protein kinase C in fear conditioning. Journal of Neuroscience, 20(16), 5906-5914.
60. Wheeler, V. C., Auerbach, W., White, J. K., Srinidhi, J., Auerbach, A., Ryan, A., et al. (1999). Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Human Molecular Genetics, 8(1), 115-122.
61. Wheeler, V. C., Gutekunst, C. A., Vrbanac, V., Lebel, L. A., Schilling, G., Hersch, S., et al. (2002). Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice. Human Molecular Genetics, 11(6), 633-640.
62. Xifro, X., Anglada-Huguet, M., Rue, L., Saavedra, A., Perez-Navarro, E., & Alberch, J. (2011). Increased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity. Molecular Neurodegeneration, 6, 74.
63. Xifro, X., Garcia-Martinez, J. M., Del, T. D., Alberch, J., & Perez-Navarro, E. (2008). Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. Journal of Neurochemistry, 105(5), 1596-1612.
64. Xifro, X., Giralt, A., Saavedra, A., Garcia-Martinez, J. M., Diaz-Hernandez, M., Lucas, J. J., et al. (2009). Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity. Neurobiology of Disease, 36(3), 461-469.
65. Zemskov, E. A., Jana, N. R., Kurosawa, M., Miyazaki, H., Sakamoto, N., Nekooki, M., et al. (2003). Pro-apoptotic protein kinase C delta is associated with intranuclear inclusions in a transgenic model of Huntington's disease. Journal of Neurochemistry, 87(2), 395-406.
66. Zhang, D., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2007). Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics, 322(3), 913-922.
67. Zhao, C., Leitges, M., & Gereau, R. W. (2011). Isozyme-specific effects of protein kinase C in pain modulation. Anesthesiology, 115(6), 1261-1270.
68. Zhong, M., Lu, Z., & Foster, D. A. (2002). Downregulating PKCδ provides a PI3 K/Akt-independent survival signal that overcomes apoptotic signals generated by c-Src overexpression. Oncogene, 21(7), 1071-1078.